[go: up one dir, main page]

PE20010127A1 - Suspension de ziprasidona - Google Patents

Suspension de ziprasidona

Info

Publication number
PE20010127A1
PE20010127A1 PE2000000480A PE0004802000A PE20010127A1 PE 20010127 A1 PE20010127 A1 PE 20010127A1 PE 2000000480 A PE2000000480 A PE 2000000480A PE 0004802000 A PE0004802000 A PE 0004802000A PE 20010127 A1 PE20010127 A1 PE 20010127A1
Authority
PE
Peru
Prior art keywords
ziprasidone
alkaline metal
metal chlorides
composition
suspension
Prior art date
Application number
PE2000000480A
Other languages
English (en)
Inventor
Daniel Ray Arenson
Hong Qi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010127A1 publication Critical patent/PE20010127A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE LA BASE LIBRE DE ZIPRASIDONA O UNA SAL DE ADICION DE ACIDOS DE ZIPRASIDONA; AGUA, POLISORBATO 20, 21, 40, 60, 61, 65, 80, 81, 85, 120; UN AGENTE DE VISCOSIDAD, DIOXIDO DE SILICIO COLOIDAL, UN AGENTE ENMASCARANTE DEL SABOR COMO CLORUROS DE METALES ALCALINOS, CLORUROS DE METALES ALCALINO TERREOS. LA COMPOSICION ES DE PREFERENCIA UNA SUSPENSION ORAL QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE LA PSICOSIS
PE2000000480A 1999-05-27 2000-05-22 Suspension de ziprasidona PE20010127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626899P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
PE20010127A1 true PE20010127A1 (es) 2001-02-06

Family

ID=22472103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000480A PE20010127A1 (es) 1999-05-27 2000-05-22 Suspension de ziprasidona

Country Status (50)

Country Link
EP (1) EP1181018B1 (es)
JP (1) JP3942827B2 (es)
KR (1) KR100477782B1 (es)
CN (1) CN1196486C (es)
AP (1) AP1409A (es)
AR (1) AR022643A1 (es)
AT (1) ATE234097T1 (es)
AU (1) AU777413B2 (es)
BG (1) BG65367B1 (es)
BR (1) BR0010990A (es)
CA (1) CA2371550C (es)
CO (1) CO5170458A1 (es)
CR (1) CR6506A (es)
CU (1) CU23223B7 (es)
CZ (1) CZ20014230A3 (es)
DE (1) DE60001649T2 (es)
DK (1) DK1181018T3 (es)
DZ (1) DZ3049A1 (es)
EA (1) EA003907B1 (es)
EE (1) EE04704B1 (es)
ES (1) ES2191618T3 (es)
GC (1) GC0000190A (es)
GE (1) GEP20033113B (es)
GT (1) GT200000081A (es)
HK (1) HK1046366B (es)
HN (1) HN2000000071A (es)
HR (1) HRP20010878B1 (es)
HU (1) HUP0201297A3 (es)
IL (2) IL145950A0 (es)
IS (1) IS2396B (es)
MA (1) MA26741A1 (es)
MX (1) MXPA01012124A (es)
MY (1) MY127891A (es)
NO (1) NO320296B1 (es)
NZ (1) NZ514764A (es)
OA (1) OA11946A (es)
PA (1) PA8495801A1 (es)
PE (1) PE20010127A1 (es)
PL (1) PL196867B1 (es)
RS (1) RS50089B (es)
SI (1) SI1181018T1 (es)
SK (1) SK284590B6 (es)
SV (1) SV2001000085A (es)
TN (1) TNSN00112A1 (es)
TR (1) TR200103392T2 (es)
TW (1) TWI263498B (es)
UA (1) UA59491C2 (es)
UY (1) UY26166A1 (es)
WO (1) WO2000072847A1 (es)
ZA (1) ZA200109692B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
MXPA05002561A (es) * 2002-10-25 2005-05-05 Pfizer Prod Inc Nuevas formulaciones de liberacion prolongada inyectables.
BR0315663A (pt) * 2002-10-25 2005-08-30 Pfizer Prod Inc Formulações de depósito de agentes ativos de aril-heterocìclicos na forma de uma suspensão
EP1418492B1 (en) 2002-11-05 2017-09-20 LG Electronics, Inc. Touch screen mounting assembly for LCD monitor
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
SG162811A1 (en) * 2005-06-20 2010-07-29 Elan Pharma Int Ltd Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
JP4336380B1 (ja) * 2008-11-06 2009-09-30 塩野義製薬株式会社 水懸濁性を向上させた細粒剤
JP6272730B2 (ja) * 2014-05-21 2018-01-31 救急薬品工業株式会社 速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations

Also Published As

Publication number Publication date
EP1181018A1 (en) 2002-02-27
KR100477782B1 (ko) 2005-03-21
HRP20010878A2 (en) 2003-06-30
BR0010990A (pt) 2002-03-05
UY26166A1 (es) 2000-12-29
NO20015755L (no) 2002-01-23
SK16782001A3 (sk) 2002-09-10
DK1181018T3 (da) 2003-04-22
AU777413B2 (en) 2004-10-14
KR20020048307A (ko) 2002-06-22
AU4138500A (en) 2000-12-18
AR022643A1 (es) 2002-09-04
TNSN00112A1 (fr) 2005-11-10
EE200100633A (et) 2003-02-17
SK284590B6 (sk) 2005-07-01
CU23223B7 (es) 2007-08-30
HK1046366A1 (en) 2003-01-10
BG65367B1 (bg) 2008-04-30
GC0000190A (en) 2006-03-29
CO5170458A1 (es) 2002-06-27
CR6506A (es) 2004-03-24
NO320296B1 (no) 2005-11-21
UA59491C2 (uk) 2003-09-15
HUP0201297A3 (en) 2005-09-28
IL145950A0 (en) 2002-07-25
HRP20010878B1 (en) 2007-03-31
CZ20014230A3 (cs) 2002-08-14
DZ3049A1 (fr) 2004-03-27
CA2371550A1 (en) 2000-12-07
NO20015755D0 (no) 2001-11-26
MY127891A (en) 2006-12-29
AP2001002346A0 (en) 2001-12-31
CN1352560A (zh) 2002-06-05
HK1046366B (zh) 2005-07-29
CA2371550C (en) 2007-01-02
MXPA01012124A (es) 2002-06-04
DE60001649D1 (de) 2003-04-17
EA003907B1 (ru) 2003-10-30
OA11946A (en) 2006-04-13
IS2396B (is) 2008-08-15
EE04704B1 (et) 2006-10-16
RS50089B (sr) 2009-01-22
YU76701A (sh) 2005-07-19
PA8495801A1 (es) 2001-12-14
ES2191618T3 (es) 2003-09-16
ATE234097T1 (de) 2003-03-15
TWI263498B (en) 2006-10-11
NZ514764A (en) 2004-04-30
JP2003500449A (ja) 2003-01-07
EP1181018B1 (en) 2003-03-12
TR200103392T2 (tr) 2002-11-21
AP1409A (en) 2005-06-13
JP3942827B2 (ja) 2007-07-11
BG106153A (bg) 2002-06-28
HUP0201297A2 (en) 2002-08-28
PL352826A1 (en) 2003-09-08
HN2000000071A (es) 2001-02-02
DE60001649T2 (de) 2003-08-21
ZA200109692B (en) 2002-11-26
SV2001000085A (es) 2001-11-08
GT200000081A (es) 2001-11-16
IS6134A (is) 2001-10-30
IL145950A (en) 2007-12-03
MA26741A1 (fr) 2004-12-20
PL196867B1 (pl) 2008-02-29
CN1196486C (zh) 2005-04-13
GEP20033113B (en) 2003-11-25
EA200101131A1 (ru) 2002-04-25
WO2000072847A1 (en) 2000-12-07
SI1181018T1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
PE20010127A1 (es) Suspension de ziprasidona
CO5700797A2 (es) Composicion de farmaco conjugado
BG106681A (en) Solutions containing epinastine
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
BRPI9811803B8 (pt) comprimido multiparticular aperfeiçoado de dissolução rápida
ZA908940B (en) Stabilised aqueous solutions of 3-isothiazolinones
ES2078576T3 (es) Derivados de benzacepina como antagonistas de la vasopresina.
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
PE44595A1 (es) Enjuague bucal concentrado para un suministro eficiente de agentes antimicrobianos
BG106602A (en) Formulation of substituted benzimidazoles
BR0008445A (pt) Emulsões pit
FR2825273B1 (fr) Composition pour le traitement des signes cutanes du vieillissement
ES2052977T3 (es) Composicion que contiene bismuto.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
DE60219462D1 (de) Verdickte wässrige zusammensetzungen
BR0115026A (pt) Composição agroquìmica
DE60208210D1 (de) Konzentriertes kapsulemittel für detergenz- oder körperpflegezusammensetzungen
NO994692D0 (no) Emulgert geleringsmiddel
ES2101815T3 (es) Composicion para la desinfeccion del agua por el procedimiento de electrocloracion y utilizacion de esta composicion.
WO2003051297A3 (en) Aqueous ifosfamide composition
ES2149736T1 (es) Composiciones farmaceuticas conteniendo derivados de tienopiridina estables y libres de antioxidantes.
DE60140454D1 (de) Flüssigkeit für herzstillstand
RS50279B (sr) Dezinfekciono sredstvo za suzbijanje sive truleži maline i njegova upotreba
ES2181415T3 (es) Composicion acuosa ionica que contiene levomentol.
MX9207338A (es) Composicion de enjuague bucal.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed